A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
An independent group of medical experts with the U.S. Preventative Services Task Force recommends that men of all ages no longer be screened using the prostate-specific antigen blood test to check for ...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...
In a new study published in the journal Nature Genetics, Haolong Li, PhD, a researcher at Fred Hutch Cancer Center, and colleagues developed a way to monitor androgen receptor levels inside living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results